Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported preclinical data showing that prostate cancer candidate GNE-049 blocked expression of key proliferative genes and reduced tumor growth. In patient-derived xenograft mouse models of prostate cancer, twice-daily oral GNE-049 significantly suppressed several androgen receptor target genes, including prostate-specific antigen (PSA; KLK3), transmembrane protease serine 2 (TMPRSS2) and FK506 binding protein 5 (FKBP5), vs. vehicle controls. In the mice, GNE-049 reduced tumor growth by 55% at day 18 compared to 21% for Xtandi enzalutamide, an oral androgen receptor antagonist from Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE). Data were published in Cancer Research...